BMS-833923 - CAS 1059734-66-5
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Publictions citing BOC Sciences Products
  • >> More
1.Hedgehog pathway as a potential treatment target in human cholangiocarcinoma.
Riedlinger D1, Bahra M, Boas-Knoop S, Lippert S, Bradtmöller M, Guse K, Seehofer D, Bova R, Sauer IM, Neuhaus P, Koch A, Kamphues C. J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):607-15. doi: 10.1002/jhbp.107. Epub 2014 Apr 15.
BACKGROUND: Innovative treatment concepts targeting essential signaling pathways may offer new chances for patients suffering from cholangiocarcinoma (CCC). For that, we performed a systematic molecular genetic analysis concerning the Hedgehog activity in human CCC samples and analyzed the effect of Hh inhibition on CCC cells in vitro and in vivo.
2.Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.
Gibson MK1, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA. Ann Surg. 2013 Jul;258(1):82-8. doi: 10.1097/SLA.0b013e318270500d.
BACKGROUND: Activated hedgehog (Hh) pathway is associated with development of both Barrett esophagus (BE) and esophageal adenocarcinoma (EAC). We hypothesize that blockade of the Hh pathway with smoothened (Smo) inhibitor can prevent the development of BE/EAC in the Levrat model, in which induced gastroduodenoesophageal reflux (GDER) leads to esophageal carcinogenesis.
3.Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.
Lauressergues E1, Heusler P1, Lestienne F1, Troulier D2, Rauly-Lestienne I1, Tourette A1, Ailhaud MC1, Cathala C1, Tardif S1, Denais-Laliève D3, Calmettes MT3, Degryse AD3, Dumoulin A2, De Vries L1, Cussac D1. Pharmacol Res Perspect. 2016 Mar 4;4(2):e00214. doi: 10.1002/prp2.214. eCollection 2016.
The Hedgehog (HH) pathway has been linked to the formation of basal cell carcinoma (BCC), medulloblastoma, and other cancers. The recently approved orally active drugs vismodegib (GDC-0449) and sonidegib (LDE-225) were not only efficacious for the treatment of advanced or metastatic BCC by antagonizing the smoothened (SMO) receptor, but also produced important side effects, limiting their use for less invasive BCC. Herein, we compared a large series of SMO antagonists, including GDC-0449 and LDE-225, the clinically tested BMS-833923, CUR-61414, cyclopamine, IPI-926 (saridegib), itraconazole, LEQ-506, LY-2940680 (taladegib), PF-04449913 (glasdegib), and TAK-441 as well as preclinical candidates (PF-5274857, MRT-83) in two SMO-dependent cellular assays and for G-protein activation. We report marked differences in inhibitor potencies between compounds as well as a notable disparity between the G-protein assay and the cellular tests, suggesting that classification of drugs is assay dependent.
4.Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR1, Lear JT. Br J Dermatol. 2013 Jul;169(1):53-7. doi: 10.1111/bjd.12311.
Basal cell carcinoma (BCC) is the most common cancer in the U.K. and its incidence is increasing. Vismodegib, a hedgehog pathway inhibitor, has recently been licensed by the U.S. Food and Drug Administration for treatment of advanced BCC. Phase 2 trials have demonstrated efficacy in cases of locally advanced and metastatic BCC, as well as cases of hereditary basal cell naevus (Gorlin) syndrome. Side-effects are frequent and considerable and include myalgia, taste disturbance, alopecia, weight loss and fatigue. Further research is needed to investigate means of circumventing these side-effects, and longitudinal data are required to assess the long-term benefits of, and the nature of resistance to, this novel class of agents. Alternative hedgehog inhibitors are currently in clinical development. We review the current data pertaining to this novel treatment modality and discuss its likely future role in the management of BCC.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Smo Products

CAS 1258861-20-9 Taladegib

(CAS: 1258861-20-9)

Taladegib binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling.

CAS 4449-51-8 Cyclopamine

(CAS: 4449-51-8)

Cyclopamine (11-deoxojervine) is a naturally occurring chemical that belongs to the group of steroidal jerveratrum alkaloids. It is a teratogen isolated from th...

CAS 1373615-35-0 PF-5274857

(CAS: 1373615-35-0)

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and can ...

(CAS: 691392-89-9)

MS0022 is a SMO antagonist. It showed effective Hh signaling pathway inhibition at the level of SMO in the low nM range, and Hh pathway inhibition downstream of...

CAS 935273-79-3 MK-4101

(CAS: 935273-79-3)

MK-4101 is a potent and selective SMO Inhibitor of the Hedgehog Pathway with anti-tumor activity. MK-4101 targets the Hh pathway in tumor cells, showing the max...

(CAS: 1204975-42-7)

This active molecular is a Smoothened (Smo) antagonist with potential antitumor activity. LEQ506 selectively binds to the Hedgehog(Hh) ligand cell surface recep...

CAS 483367-10-8 Purmorphamine

(CAS: 483367-10-8)

Purmorphamine, under the IUPAC name 9-Cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthalenyloxy)-9H-purin-6-amine, is a cell-permeable 6,9-trisubstituted pur...

CAS 956697-53-3 Sonidegib

(CAS: 956697-53-3)

Sonidegib, also known as, erismodegib (LDE225, NVP-LDE225) is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic ac...

MRT-92 HCl salt
(CAS: 1428307-52-1)

MRT-92 is a selective Smoothened (Smo) receptor inhibitor. It shows subnanomolar antagonist activity against Smo in various Hh cell-based assays. MRT-92 inhibit...

MRT-83 hydrochloride
(CAS: 1359944-60-7)

MRT-83 is a Smoothened (Smo) antagonist. It can block Hedgehog (Hh) signaling in various assays. MRT-83 can also inhibit Bodipy-cyclopamine binding to human and...

CAS 1059734-66-5 BMS-833923

(CAS: 1059734-66-5)

CAS 912545-86-9 SAG

(CAS: 912545-86-9)

SAG is a potent Smoothened (Smo) receptor agonist (Kd = 59 nM); sag antagonizes cyclopamine action at the Smo receptor.

(CAS: 1263131-92-5)

This active molecular is a novel potent Smoothened antagonist. MRT-83 blocks Hedgehog (Hh) signaling in various assays and IC50 can be in nmol range, showing gr...

CAS 1095173-27-5 Glasdegib

(CAS: 1095173-27-5)

Glasdegib, als known as PF-04449913, is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic act...

Chemical Structure

CAS 1059734-66-5 BMS-833923

Quick Inquiry

Verification code

Featured Items